tradingkey.logo

Neuropace Inc <NPCE.OQ> expected to post a loss of 24 cents a share - Earnings Preview

ReutersMay 10, 2025 12:11 AM
  • Neuropace Inc NPCE.OQ NPCE.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • The Mountain View California-based company is expected to report a 20.5% increase in revenue to $21.847 million from $18.12 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Neuropace Inc is for a loss of 24 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Neuropace Inc is $17.00​, above​ its last closing price of $12.89. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.22

-0.22

-0.18

Beat

19.2

Sep. 30 2024

-0.27

-0.27

-0.19

Beat

29.2

Jun. 30 2024

-0.30

-0.30

-0.26

Beat

13.3​

Mar. 31 2024

-0.32

-0.32

-0.32

Met

0.5

​​Dec. 31 2023

-0.30

-0.31

-0.23

Beat

27

Sep. 30 2023

-0.41

-0.41

-0.28

Beat

31.7​

Jun. 30 2023

-0.46

-0.46

-0.36

Beat

22.6

Mar. 31 2023

-0.46

-0.46

-0.41

Beat

10.1

This summary was machine generated May 10 at 00:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles